Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Common Equity (2023 - 2025)

Profound Medical (PROF) has 3 years of Common Equity data on record, last reported at $66.4 million in Q4 2025.

  • For Q4 2025, Common Equity rose 9.95% year-over-year to $66.4 million; the TTM value through Dec 2025 reached $66.4 million, up 9.95%, while the annual FY2025 figure was $66.4 million, 9.95% up from the prior year.
  • Common Equity reached $66.4 million in Q4 2025 per PROF's latest filing, up from $32.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $66.4 million in Q4 2025 and bottomed at $30.7 million in Q3 2024.
  • Average Common Equity over 3 years is $43.9 million, with a median of $39.3 million recorded in 2025.
  • Peak YoY movement for Common Equity: soared 93.51% in 2024, then grew 0.94% in 2025.
  • A 3-year view of Common Equity shows it stood at $31.2 million in 2023, then skyrocketed by 93.51% to $60.4 million in 2024, then grew by 9.95% to $66.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $66.4 million in Q4 2025, $32.1 million in Q3 2025, and $39.3 million in Q2 2025.